Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
2,406.05
0.00 EUR
−283.34 K EUR
44.57 M EUR
25.38 M
About Photocure ASA
Sector
Industry
CEO
Daniel Schneider
Website
Headquarters
Oslo
Founded
1993
Identifiers
2
ISIN NO0010000045
Photocure ASA engages in the development and commercialization of pharmaceutical products based on photodynamic technology. Its products include Metvix for nonmelanoma skin cancer, Hexvix/Cysview for better detection and management of bladder cancer, and Cevira which is a photodynamic drug-device combination product for non-surgical treatment of high-grade cervical dysplasia. The company operates through the Commercial Franchise and Development Portfolio segments. The Commercial Franchise segment includes the sale of Hexvix/Cysview in the U.S. and Europe and other sales from partners and other products. The Development Portfolio segment focuses on the development of pipeline products. The company was founded in 1997 and is headquartered in Oslo, Norway.
Related stocks
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange Photocure ASA stocks are traded under the ticker PHS.
We've gathered analysts' opinions on Photocure ASA future price: according to them, PHS price has a max estimate of 7.24 EUR and a min estimate of 5.96 EUR. Watch PHS chart and read a more detailed Photocure ASA stock forecast: see what analysts think of Photocure ASA and suggest that you do with its stocks.
Yes, you can track Photocure ASA financials in yearly and quarterly reports right on TradingView.
Photocure ASA is going to release the next earnings report on Feb 18, 2026. Keep track of upcoming events with our Earnings Calendar.
Photocure ASA revenue for the last quarter amounts to 11.48 M EUR, despite the estimated figure of 11.22 M EUR. In the next quarter, revenue is expected to reach 11.98 M EUR.
PHS net income for the last quarter is 339.87 K EUR, while the quarter before that showed 408.72 K EUR of net income which accounts for −16.85% change. Track more Photocure ASA financial stats to get the full picture.
No, PHS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jan 29, 2026, the company has 101 employees. See our rating of the largest employees — is Photocure ASA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Photocure ASA EBITDA is 13.00 M EUR, and current EBITDA margin is 28.30%. See more stats in Photocure ASA financial statements.
Like other stocks, PHS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Photocure ASA stock right from TradingView charts — choose your broker and connect to your account.